SU2C, Genentech announce second “catalyst” collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stand Up To Cancer announced a second SU2C Catalyst collaboration with Genentech, a member of the Roche Group, aimed at accelerating the development of new cancer treatments and combination therapies through clinical trials using Genentech medicines, including both commercial and pre-commercial treatments.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login